Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Oct;9(5):1165-1166.
doi: 10.21037/gs.2020.03.26.

Does ethnicity matter in chemotherapy for breast cancer?

Andrzej L Komorowski  1 , Maksymilian Kruczala  2
Affiliations
Editorial

Does ethnicity matter in chemotherapy for breast cancer?

Andrzej L Komorowski et al. Gland Surg. 2020 Oct.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/gs.2020.03.26). The authors have no conflicts of interest to declare.

Comment on

References

    1. Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012;13:25-32. 10.1016/S1470-2045(11)70336-9 - DOI - PubMed
    1. Chow LWC, Biganzoli L, Leo AD, et al. Toxicity profile differences of adjuvant docetaxel/cyclophosphamide (TC) between Asian and Caucasian breast cancer patients. Asia Pac J Clin Oncol 2017;13:372-8. 10.1111/ajco.12682 - DOI - PubMed
    1. Szloch J, Marczyk E, Kołodziej-Rzepa M, et al. Impact of different type of cancer treatment on the effectiveness of breast reconstruction. Gland Surg 2016;5:444-9. 10.21037/gs.2016.05.06 - DOI - PMC - PubMed
    1. Shao Z, Pang D, Yang H, et al. Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia: The PEONY Phase 3 Randomized Clinical Trial. JAMA Oncol 2020;6:e193692. - PMC - PubMed
    1. Han HS, Reis IM, Zhao W, et al. Racial differences in acute toxicities of neoadjuvant or adjuvant chemotherapy in patients with early-stage breast cancer. Eur J Cancer 2011;47:2537-45. 10.1016/j.ejca.2011.06.027 - DOI - PubMed